David Wildes

2.1k citations

24 papers · 335 indexed · h-index 10

Impact in

Oncology
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
Immunology
- Galectins and Cancer Biology

Papers in ⓘ

Molecular Biology 20
- Protein Tyrosine Phosphatases 8
- Signaling Pathways in Disease 7
- Ubiquitin and proteasome pathways 5
- Biochemical and Molecular Research 4
Oncology 9
- Peptidase Inhibition and Analysis 6

Co-authors: James A. Wells (1 shared paper)Mallika Singh (17 shared papers)Jacqueline A.M. Smith (14 shared papers)Elena S. Koltun (11 shared papers)Adrian L. Gill (11 shared papers)Christopher J. Schulze (7 shared papers)Robert J. Nichols (9 shared papers)Elsa Quintana (4 shared papers)
Journals: Cancer Research (14 papers)Molecular Cancer Therapeutics (2 papers)European Journal of Cancer (2 papers)Frontiers in Oncology (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: United States

In The Last Decade

David Wildes

23 papers receiving 331 citations

Peers

Countries citing papers authored by David Wildes

Since Specialization

Citations

This map shows the geographic impact of David Wildes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wildes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wildes more than expected).

Fields of papers citing papers by David Wildes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wildes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wildes. The network helps show where David Wildes may publish in the future.

Co-authors

The 25 scholars most cited alongside David Wildes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Wildes Line = papers co-authored together David Wildes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Sampling the N-terminal proteome of human blood Proceedings of the National Academy of Sciences ·David Wildes, James A. Wells	2010	93
2	Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment Cancer Research ·Elsa Quintana, Christopher J. Schulze, Darienne R. Myers, Tiffany J. Choy, Kasia Mordec, David Wildes, Nataliya Tobvis Shifrin, Amira Belwafa, Elena S. Koltun, Adrian L. Gill, Mallika Singh, Stephen M. Kelsey, Mark A. Goldsmith, Robert J. Nichols, Jacqueline A.M. Smith	2020	69
3	Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity Frontiers in Immunology ·Darienne R. Myers, Clare L. Abram, David Wildes, Amira Belwafa, Alia M. N. Welsh, Christopher J. Schulze, Tiffany J. Choy, Tram Nguyen, Neil Omaque, Yongmei Hu, Mallika Singh, Rich Hansen, Mark A. Goldsmith, Elsa Quintana, Jacqueline A.M. Smith, Clifford A. Lowell	2020	31
4	Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers Cancer Research ·Robert J. Nichols, Yu Chi Yang, Jim Cregg, Chris J. Schulze, Zhican Wang, Richa Dua, Jingjing Jiang, Lindsay S. Garrenton, Nicole Nasholm, Alun Bermingham, John E. Knox, Kyle J. Seamon, Michael Longhi, Kang-Jye Chou, Shaoling Li, David Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Jacqueline A.M. Smith	2022	27
5	Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models Cancer Research ·John E. Knox, Jingjing Jiang, G. Leslie Burnett, Yang Liu, Caroline E. Weller, Zhican Wang, Laura McDowell, Shelby L. Steele, Shook Chin, Kang Jye Chou, Fang Wang, Mengqi Zhong, Elena S. Koltun, David Wildes, Mallika Singh, Adrian L. Gill, Jacqueline A.M. Smith	2022	26
6	Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^MULTI(ON) inhibitor. Journal of Clinical Oncology ·W. Clay Gustafson, David Wildes, Meghan A. Rice, Bianca J. Lee, Jingjing Jiang, Zhengping Wang, Stephanie Chang, Mike Flagella, Yunming Mu, Nuntana Dinglasan, Nicole Nasholm, James Evans, Kyle J. Seamon, Jim Cregg, Alun Bermingham, Rebecca Freilich, Adrian L. Gill, Elena S. Koltun, Jacqueline A.M. Smith, Mallika Singh	2022	23
7	Abstract PR10: Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo Molecular Cancer Therapeutics ·Christopher J. Schulze, Alun Bermingham, Tiffany J. Choy, James Cregg, Gert Kiss, Abby Marquez, Denise F. Reyes, Mae Saldajeno-Concar, Caroline E. Weller, Daniel M. Whalen, Yu Chi Yang, Elena S. Koltun, Robert J. Nichols, Mallika Singh, David Wildes, Adrian L. Gill, Richard L. Hansen, Steve Kelsey, Mark A. Goldsmith, Jacqueline A.M. Smith	2019	15
8	Abstract ND03: Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor Cancer Research ·John E. Knox, G. Leslie Burnett, Caroline E. Weller, Lingyan Jiang, Dongyu Zhang, Nicole Vita, Abby Marquez, Kyle J. Seamon, Andrea Gould, Marie Ménard, Elsa Quintana, Zhe Chen, Zhican Wang, Zhengping Wang, Elena S. Koltun, Malika Singh, Jingjing Jiang, David Wildes, Jacqueline A.M. Smith, Adrian L. Gill	2024	12
9	Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia Frontiers in Oncology ·Bianca J. Lee, Sharmila Mallya, Nuntana Dinglasan, Amos Fung, Tram Nguyen, Lee-or Herzog, Joshua Thao, Edward Lorenzana, David Wildes, Mallika Singh, Jacqueline A.M. Smith, (unknown)	2021	11
10	Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models Cancer Research ·Christopher J. Schulze, Jim Cregg, Kyle J. Seamon, Yu Chi Yang, Zhican Wang, Lindsay S. Garrenton, Alun Bermingham, John E. Knox, Aidan C.A. Tomlinson, Kang-Jye Chou, Shaoling Li, David Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Robert J. Nichols, Jacqueline A.M. Smith	2022	9
11	Abstract ND07: Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor Cancer Research ·Jim Cregg, Rhonda Nichols, Yu Chi Yang, Christopher J. Schulze, Zhiqiang Wang, R Dua, Jingjing Jiang, Nicole Nasholm, John E. Knox, Kenneth B. Seamon, Michael Longhi, A. Tomlinson, Kang-Jye Chou, Shun Li, David Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Joseph A. Smith	2023	4
12	Abstract 3340: RMC-5127, a first-in-class, orally bioavailable mutant-selective RASG12V(ON) inhibitor is central nervous system (CNS)-penetrant and demonstrates anti-tumor activity in a preclinical intracranial xenograft model Cancer Research ·Zhe Chen, André Eriksson, Bianca J. Lee, Jay Dinglasan, Nilufar Montazer, Jim Cregg, Anne Edwards, Kate L. Sanders, Jacqueline A.M. Smith, David Wildes, Mallika Singh, Zhican Wang, Jingjing Jiang	2024	3
13	VALUE ADDED DEVELOPMENTS FOR POULTRY Journal of food distribution research ·David Wildes, (unknown)	1988	2
14	Abstract 1725: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma Cancer Research ·Urszula N. Wasko, Stephen A. Sastra, Carmine F. Palermo, David Wildes, Mallika Singh, Kenneth P. Olive	2023	1
15	92 (PB080): Selective Inhibition of Active KRASG13C with RMC-8839 Reveals an Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild- Type RAS Isoforms European Journal of Cancer ·Kenneth B. Seamon, Sohini Chakraborty, Yin Zhuang, Jim Cregg, A. Tomlinson, Nicole Nasholm, Mallika Singh, Jacqueline A.M. Smith, Matthew Holderfield, David Wildes	2024	1
16	Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway Cancer Research ·Jacqueline A.M. Smith, Mallika Singh, Robert J. Nichols, Elena S. Koltun, Yu Chi Yang, David Wildes, Carlos Stahlhut, Dong Hun Lee, Chris J. Schulze, Denise F. Reyes, Abby Marquez, Grace J. Lee, Shaoling Li, Christophe Marcireau, Laurent Debüssche, Mark A. Goldsmith, Zhengping Wang, Adrian L. Gill, Steve Kelsey	2020	1
17	Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer Cancer Research ·Joshua H. Choe, Julien Dilly, Eejung Kim, Lo Lai, Nicole Sindoni, Fan Yi Kong, Dennis Gong, Jaclyn Varga-Wiles, Brendan Parent, Junning Wang, Kyle J. Seamon, Jennifer A. Chan, Clint A. Stalnecker, Channing J. Der, William L. Hwang, Brian M. Wolpin, David Wildes, Joseph D. Mancias, Lewis C. Cantley, Andrew J. Aguirre	2025	1
18	Abstract 4709: The RASMULTI(ON) inhibitor RMC-7977 blocks downstream MAPK and PI3K pathway activation in KRASG12X_mutant cancers Cancer Research ·Priyanka Bapat, Kyle J. Seamon, Andrea Gould, David Wildes	2024	1
19	Abstract 4877: Allosteric inhibition of SHP2 variants containing cancer-associated activating mutations Cancer Research ·David Wildes, Naing Aay, Andreas Buckl, Daphne Hsieh, Ashutosh S. Jogalekar, Gert Kiss, Elena S. Koltun, Abby Marquez, Kevin T. Mellem, Jason M. Romero, Mae Saldajeno-Concar, Christopher J. Schulze, Chris M. Semko, Walter Won, Robert J. Nichols, Carlos Stahlhut, Christos Tzitzilonis, Adrian L. Gill, Jacqueline A.M. Smith	2018	1
20	Abstract A103: Allosteric inhibition of SHP2 induces antitumor immunity in PD-1-sensitive tumors through modulation of both innate and adaptive mechanisms Cancer Immunology Research ·Elsa Quintana, Kasia Mordec, Robert J. Nichols, David Wildes, Chris J. Schulze, Darienne R. Myers, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Stephen M. Kelsey, Mark A. Goldsmith, Jan A. Smith	2019	1

About David Wildes

David Wildes is a scholar working on Molecular Biology, Oncology, Biotechnology, Immunology and Cancer Research, having authored 24 papers that have together received 335 indexed citations. Recurring topics across this work include Protein Tyrosine Phosphatases (8 papers), Signaling Pathways in Disease (7 papers), Peptidase Inhibition and Analysis (6 papers), Ubiquitin and proteasome pathways (5 papers), Biochemical and Molecular Research (4 papers), Cancer Research and Treatments (4 papers), Galectins and Cancer Biology (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). The work is most often cited by research in Oncology (156 citations), Immunology (81 citations), Molecular Biology (241 citations), Cancer Research (37 citations) and Spectroscopy (36 citations). David Wildes has collaborated with scholars based in United States. Frequent co-authors include James A. Wells, Mallika Singh, Jacqueline A.M. Smith, Elena S. Koltun, Adrian L. Gill, Christopher J. Schulze, Robert J. Nichols, Elsa Quintana, Mark A. Goldsmith and Darienne R. Myers. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, European Journal of Cancer, Frontiers in Oncology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact